Elicera Therapeutics: Promising start for cohort 3 in ELC-301 CARMA-study - Redeye
Bildkälla: Stockfoto

Elicera Therapeutics: Promising start for cohort 3 in ELC-301 CARMA-study - Redeye

Redeye gives a short initial comment on the new promising data from the ongoing CARMA-study with ELC-301.

Redeye gives a short initial comment on the new promising data from the ongoing CARMA-study with ELC-301.
Börsvärldens nyhetsbrev